NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases

Jain, Anu; Hopkins, Katie L.; Turton, Jane F.; Doumith, Michel; Hill, Robert L.; Loy, Richard; Meunier, Danièle; Pike, Rachel; Livermore, David M.; Woodford, Neil

doi:10.1093/jac/dku084

Cited by 66 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NDM-1 was subsequently found to be widespread in the Indian subcontinent, including in environmental samples (66), and has now been reported in more than 15 countries (67). In the United Kingdom, 52% of 101 patients with NDM-producing isolates collected from 2008 to 2013 reported health care exposure or travel to the Indian subcontinent (68).…”

Section: Current Status Of Carbapenemasesmentioning

confidence: 99%

Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods

et al. 2016

View full text Add to dashboard Cite

SUMMARYCarbapenemases have become a significant mechanism for broad-spectrum β-lactam resistance inEnterobacteriaceaeand other Gram-negative bacteria such asPseudomonasandAcinetobacterspp. Intestinal carriage of carbapenemase-producing organisms (CPOs) is an important source of transmission. Isolation of carriers is one strategy that can be used to limit the spread of these bacteria. In this review, we critically examine the clinical performance, advantages, and disadvantages of methods available for the detection of intestinal carriage of CPOs. Culture-based methods (Centers for Disease Control and Prevention [CDC] protocols, chromogenic media, specialized agars, and double-disk synergy tests) for detecting carriage of CPOs are convenient due to their ready availability and low cost, but their limited sensitivity and long turnaround time may not always be optimal for infection control practices. Contemporary nucleic acid amplification techniques (NAATs) such as real-time PCR, hybridization assays, loop-mediated isothermal amplification (LAMP), or a combined culture and NAAT approach may provide fast results and/or added sensitivity and specificity compared with culture-based methods. Infection control practitioners and clinical microbiologists should be aware of the strengths and limitations of available methods to determine the most suitable approach for their medical facility to fit their infection control needs.

show abstract

Section: Current Status Of Carbapenemasesmentioning

confidence: 99%

Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Of note, avibactam does not inhibit metallo-␤-lactamases, such as New Delhi metallo-␤-lactamase-1 (NDM-1), whose production is an increasingly prevalent mechanism of carbapenem resistance in Enterobacteriaceae in some countries (11). In a recent study from the United Kingdom, colistin resistance was observed in 10% of NDM-1-producing CRE (12). In addition to ceftazidime-avibactam, several other agents with anti-CRE activity are in late clinical development and may provide in the near future additional treatment options for colistin-resistant CRE infections, except for those caused by strains producing a metallo-␤-lactamase.…”

mentioning

confidence: 99%

Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae: Are We at the End of the Road?

Duin

Doi

2015

J Clin Microbiol

View full text Add to dashboard Cite

Carbapenem-resistantKlebsiella pneumoniaestrains that produceK. pneumoniaecarbapenemase (KPC) have spread globally in the last decade. Colistin is a key agent in treating infections caused by this pathogen. In this issue of theJournal of Clinical Microbiology, Giani et al. (T. Giani, F. Arena, G. Vaggelli, V. Conte, A Chiarell, L. H. De Angelis, R. Fornaini, M. Grazzini, F. Niccolini, P. Pecile, and G. M. Rossolini, J Clin Microbiol 53:3341–3344, 2015,http://dx.doi.org/10.1128/JCM.01017-15) describe a sustained outbreak of colistin-resistant KPC-producingK. pneumoniae.

show abstract

“…En nuestra serie, todos los pacientes fueron mayores de 40 años y habían sido atendidos por el servicio de emergencia; 5/9 (55,5%) tuvieron intervención neuroquirúrgica y 4/9 (44,4%) fueron catalogados como colonizantes (dos urocultivos, un cultivo de punta de catéter y un cultivo de aspirado bronquial). En la descripción más grande de carbapenemasas NDM, descrita en el Reino Unido, hallaron que más del 60% fueron varones, en su mayoría mayores de 60 años y donde más del 50% presentaron historia previa de viaje o contacto con zonas de alta endemicidad (19) . En la presente serie no se encontró antecedente de viaje a zonas de alta endemicidad en ninguno de los casos.…”

Section: Discussionunclassified

Klebsiella pneumoniae nueva Delhi metalo-betalactamasa en el hospital nacional Dos de Mayo. Lima, Perú

Resurrección-Delgado

Montenegro-Idrogo

Chiappe-Gonzalez

et al. 2017

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

RESUMENLa emergencia de enterobacterias productoras de carbapenemasas de tipo Nueva Delhi Metalo beta-lactamasas (NDM), representan, hoy en día, un verdadero problema de salud pública mundial. La presencia de este mecanismo de resistencia limita o anula las opciones terapéuticas para combatir a estas bacterias. En Latinoamérica, las cifras son cada vez más elevadas, pues se reportan en Guatemala, Colombia, Chile, Argentina, entre otros. Perú no ha descrito, hasta la fecha, la presencia de este patrón de resistencia; sin embargo, desde hace varios años se presume de su existencia. Se describen nueve casos de Klebsiella pneumoniae NDM, como agentes infecciosos o colonizantes, en pacientes críticamente enfermos, en su mayoría con patología neuroquirúrgica, del Hospital Nacional Dos de Mayo, en Lima -Perú. Los pacientes de la serie descrita a continuación, representan los primeros reportes de Klebsiella pneumoniae NDM en el Perú. Palabras clave: Klebsiella pneumoniae, Nueva Delhi Metalo beta-lactamasa, Enterobacteriaceae, carbapenemasa, Latinoamérica. (fuente: DeCS BIREME). Klebsiella pneumoniae NEW DELHI METALO-LACTAMASE IN A PERUVIAN NATIONAL HOSPITAL ABSTRACTThe emergence of Enterobacteria producing carbapenemases of type New Delhi Metalo beta-lactamases (NDM), represent, today, a real problem of world public health. The presence of this resistance mechanism limits or nullifies the therapeutic options to combat these bacteria. In Latin America, the figures are getting higher, as they are reported in Guatemala, Colombia, Chile, Argentina, among others. Peru has not, to date, described the presence of this resistance pattern; however for several years it has been presumed to exist. Nine cases of Klebsiella pneumoniae NDM are described, as infectious or colonizing agents, in critically ill patients, mostly with neurosurgical pathology, of Hospital Nacional Dos de Mayo in Lima -Peru. The patients in the series described below represent the first reports of Klebsiella pneumoniae NDM in Peru.

show abstract

NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases

Abstract: Gram-negative bacteria with NDM carbapenemases are a growing challenge, especially for elderly hospitalized patients, including those with healthcare contact in the Indian subcontinent, and leave few therapeutic options. UK outbreaks remain rare and contained.

Cited by 66 publications

References 23 publications

Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods

Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods

Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae: Are We at the End of the Road?

Klebsiella pneumoniae nueva Delhi metalo-betalactamasa en el hospital nacional Dos de Mayo. Lima, Perú

Contact Info

Product

Resources

About